UNMC Physician, Julie Bridge, M.D., Honored with Award for Pioneering Work in Genetic Research

A University of Nebraska Medical Center genetic researcher, Julia Bridge,

M.D., has received the Kappa Delta Ann Doner Vaughn Award for 1999 from

the American Academy of Orthopaedic Surgeons. The award is the highest

recognition given for original research by the academy, which is comprised

of 14,000 members. Only two researchers a year receive the award.

Dr. Bridge, a pathologist and geneticist, received the award for her

pioneering genetic research at the University of Nebraska Medical Center.

The award recognizes the work she published in, “A Genetic Approach to

Bone and Soft Tissue Tumors,” a culmination of research on more than 3,500

benign and malignant bone and soft tissue tumors. The award honors excellence

and significant contributions in orthopaedic research and provides a $20,000

stipend.

This is a very special honor for Dr. Bridge and the medical center,

said Harold M. Maurer, M.D., UNMC chancellor. Not only does it speak highly

of her research in this area, but she is the only one from Nebraska who

has ever received this award and shes a pathologist, not an orthopaedic

surgeon, to whom the honor is usually bestowed.

Dr. Bridge, an associate professor in the departments of pathology/microbiology,

pediatrics and orthopaedic surgery, and a team of eight laboratory researchers,

were the first to identify and categorize genetic defects and what happens

in the cells of certain cancers — some 20 different types of rare bone

and soft tissue cancer. Soft tissue cancers are those of the muscle, fat,

nerves or blood vessels and includes Ewing’s sarcoma and rhabdomyosarcoma.

“A normal cell has 46 chromosomes, Dr. Bridge said. We look at the

number and structure of the chromosomes that change in the cells of tumors.

By identifying the chromosome change, we can determine which genes are

altered or disrupted.”

Dr. Bridges research in this area began in 1985, when she was in her

second year of residency training.

“This research has resulted in the development of new diagnostic tests

for these cancers, as well as better defining how aggressive we need to

treat the patient. She said identifying chromosomal abnormalities which

are specific or unique for different types of bone and soft tissue tumors

is one of the best tools she and her colleagues have ever had to determine

the exact type of bone or soft tissue tumor a patient has.

“Now we can make an accurate diagnosis of what kind of cancer a patient

has. Prior to this research, bone and soft tissue tumors were often misclassified

histologically. It was because we had no better way of determining what

kind of tumors they were. It is great to be able to start identifying defective

genes. If a certain gene is responsible for cancer, if we can arrest or

repair it, perhaps we can stop tumor growth. We can use this information

for research but it also has clinical applications.”

Biopsied tumors from all over the United States are evaluated at UNMC’s

Department of Pathology and Microbiology and the labs of the Munroe-Meyer

Institute for Rehabilitation and Genetics.

“It’s a team effort,” Dr. Bridge said. “We’ve been fortunate to have

really good people in the lab. This award acknowledged that UNMC researchers

have developed an expertise in this area over the last 10 years. The result

is we attract patients regionally and nationally and institutions seek

our expertise.”

Dr. Bridge earned her bachelors and medical degrees from UNMC in 1984.

From 1984 to 1988, she completed her pathology residency training at the

University of Kansas Medical Center in Kansas City followed by a two-year

fellowship in cytogenetics at UNMC. She completed a one-year fellowship

in molecular genetics at the Southwest Biomedical Research Institute in

Scottsdale, Ariz.

Before joining UNMC in 1990 as a consulting physician she was a clinical

assistant professor in the Department of Pathology and Oncology at the

University of Kansas Medical Center.

UNMC is the only public academic health science center in the state.

Through its commitment to research, education and patient care, UNMC has

established itself as one of the country’s leading centers for cancer research

and treatment and solid organ transplantation. More than $34 million in

research grants and contracts are awarded to UNMC scientists annually. 

In addition, UNMC’s educational programs are responsible for training more

health professionals practicing in Nebraska than any other institution.